2020
DOI: 10.1016/j.jmb.2020.11.005
|View full text |Cite
|
Sign up to set email alerts
|

The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
12
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 11 publications
(12 citation statements)
references
References 43 publications
0
12
0
Order By: Relevance
“…In addition, we show data for α-synuclein in the presence and absence of a therapeutic peptide (KDGIVNGVKA), designed to prevent aggregation to the toxic species (as we have reported previously) ( Jain et al, 2013 ). This peptide is based on residues 45–54 of the α-synuclein sequence ( Figure 4A ; green coloration), and therefore, binding will be in that location ( Meade et al, 2020 ), and we do not expect the variants to alter this binding given they are not within this sequence. This peptide has been shown to bind to a partially aggregated form of α-synuclein ( Meade et al, 2020 ).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, we show data for α-synuclein in the presence and absence of a therapeutic peptide (KDGIVNGVKA), designed to prevent aggregation to the toxic species (as we have reported previously) ( Jain et al, 2013 ). This peptide is based on residues 45–54 of the α-synuclein sequence ( Figure 4A ; green coloration), and therefore, binding will be in that location ( Meade et al, 2020 ), and we do not expect the variants to alter this binding given they are not within this sequence. This peptide has been shown to bind to a partially aggregated form of α-synuclein ( Meade et al, 2020 ).…”
Section: Resultsmentioning
confidence: 99%
“…This peptide is based on residues 45–54 of the α-synuclein sequence ( Figure 4A ; green coloration), and therefore, binding will be in that location ( Meade et al, 2020 ), and we do not expect the variants to alter this binding given they are not within this sequence. This peptide has been shown to bind to a partially aggregated form of α-synuclein ( Meade et al, 2020 ). Figure 4B shows the value extracted from the REES data from independent fits [no shared value] to each of the α-synuclein variants and in the presence of the therapeutic peptide.…”
Section: Resultsmentioning
confidence: 99%
“…25 In addition, we show data for α-synuclein in the presence and absence of a therapeutic peptide (KDGIVNGVKA), designed to prevent aggregation to the toxic species (as we have reported previously). 26 This peptide is based on residues 45-54 of the αsynuclein sequence (Figure 3A; green colouration) and therefore binding will be in that location. 26 This peptide has been shown to bind to a partially aggregated form of αsynuclein.…”
Section: Changes In Bothmentioning
confidence: 99%
“…26 This peptide is based on residues 45-54 of the αsynuclein sequence (Figure 3A; green colouration) and therefore binding will be in that location. 26 This peptide has been shown to bind to a partially aggregated form of αsynuclein. 26 Figure 3B shows the ( ) value extracted from the REES data from independent fits (no shared ( ) value) to each of the α-synuclein variants and in the presence of the therapeutic peptide.…”
Section: Changes In Bothmentioning
confidence: 99%
See 1 more Smart Citation